A. J. Armstrong Et Al. , "Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , vol.33, ELECTR NETWORK, 2022
Armstrong, A. J. Et Al. 2022. Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , (ELECTR NETWORK).
Armstrong, A. J., Saad, F., Thiery-Vuillemin, A., Oya, M., Shore, N. D., Mehra, N., ... ÖZGÜROĞLU, M.(2022). Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial . Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK
Armstrong, A. Et Al. "Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022
Armstrong, A. J. Et Al. "Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , ELECTR NETWORK, 2022
Armstrong, A. J. Et Al. (2022) . "Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , ELECTR NETWORK.
@conferencepaper{conferencepaper, author={A. J. Armstrong Et Al. }, title={Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial}, congress name={Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)}, city={}, country={ELECTR NETWORK}, year={2022}}